2019 CYIR Finalized
45 2. LTL has been shown in prior studies to be a prognostic bio- marker in patients with IPF. 3. These data suggest that LTL could also have the potential to be a pharmacogenomic biomarker in patients with IPF. 4. This is a post-hoc analysis of a clinical trial population not designed to assess for this interaction and requires further investigation. PREDICTING OUTCOMES IN IDIOPATHIC PULMONARY FIBROSIS Jacob J, Bartholmai BJ, Rajagopalan S, van Moorsel CHM, van Es HW, van Beek FT, Struik MHL, Kokosi M, Egashira R, Brun AL, Nair A, Walsh SLF, Cross G, Barnett J, de Lauretis A, Judge EP, Desai S, Karwoski R, Ourselin S, Renzoni E, Maher TM, Altmann A, Wells AU. Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis. Am J Respir Crit Care Med. 2018;198(6):767-76. Summary Idiopathic pulmonary fibrosis (IPF) is a progressive dis- ease. Forced vital capacity (FVC) is the primary measure of outcome in IPF and has been correlated with survival. While there is a degree of measurement variation, a 10% FVC decline has been a surrogate marker of mortal- ity. Cohort enrichment strategies in IPF clinical trials have been a focus in order to create more homogeneous study populations who are likely to experience increased clinical events. This study aimed to determine if computer analysis of computed tomographic (CT) imaging could be used to predict mortality. They compared this to other measures of mortality prediction and whether or not this modality could be used to enrich a clinical trial population. The computer scored CT variables using CALIPER (Computer-Aided Lung Informatics for Pathology Evaluation and Rating) software, which included a vessel-related structure (VRS) score. Using a derivation (n=247) and validation (n=284) cohort, they found that the VRS score predicted survival and FVC decline at 12 months. These computer derived scores were also accentuated in less extensive disease. Using a VRS score of greater than 4.4%, they suggest this would reduce the sample size of an IPF clinical trial by 25%. Comments 1. Automated computer scoring techniques may help inform prognosis in patients with IPF, particularly in those with less extensive disease at baseline. 2. These computer algorithms may also help clinical trial efficiency by reducing a trial sample size by approximately 25%. 3. The main limitation of this methodology is the requirement of noncontrast volumetric imaging acquired to generate appropri- ate reconstruction algorithms, as misclassification of radiologic features could occur depending on the technique used and the quality of the imaging. OTHER ARTICLES OF INTEREST Guideline Statements and Diagnostic Modalities in ILD Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T, Nicholson AG, Knight SL, Raoof S, Richeldi L, Ryerson CJ, Ryu JH, Wells AU. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. The Lancet Respiratory medicine. 2018;6(2):138-53. Walsh SLF, Calandriello L, Silva M, Sverzellati N. Deep learning for classifying fibrotic lung disease on high- resolution computed tomography: a case-cohort study. The Lancet Respiratory medicine. 2018;6(11):837-45. Lederer DJ, Martinez FJ. Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018;378(19):1811-23. Prognosis in ILD Dotan Y, Vaidy A, Shapiro WB, Zhao H, Dass C, Toyoda Y, Marchetti N, Shenoy K, Cordova FC, Criner GJ, Mamary AJ. Effect of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Lung Transplantation Outcome. Chest. 2018;154(4):818-26. Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR. Prognostic and predictive bio- markers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials. The Lancet Respiratory medicine. 2018;6(8):615-26. Nolan CM, Maddocks M, Maher TM, Banya W, Patel S, Barker RE, Jones SE, George P, Cullinan P, Man WD. Gait speed and prognosis in patients with idiopathic pulmo- nary fibrosis: a prospective cohort study. Eur Respir J. 2018. Jacob J, Hirani N, van Moorsel CHM, Rajagopalan S, Murchison JT, van Es HW, Bartholmai BJ, van Beek FT, Struik MHL, Stewart GA, Kokosi M, Egashira R, Brun AL, Cross G, Barnett J, Devaraj A, Margaritopoulos G, Karwoski R, Renzoni E, Maher TM, Wells AU. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J. 2019;53(1). The Role of Genetics in ILD Dressen A, Abbas AR, Cabanski C, Reeder J, Ramalingam TR, Neighbors M, Bhangale TR, Brauer MJ, Hunkapiller J, Reeder J, Mukhyala K, Cuenco K, Tom J, Cowgill A, ILD
Made with FlippingBook
RkJQdWJsaXNoZXIy MTM1ODMw